eprizero 5 mg/ml užpilamasis tirpalas mėsiniams ir pieniniams galvijams
norbrook laboratories (ireland) limited (airija) - užpilamasis tirpalas - 1 ml tirpalo yra: eprinomektino - 5 mg. - gydyti, esant užsikrėtimui virškinamojo trakto, plaučių nematodais, gyliais, niežų erkėmis, utėlėmis, plaukagraužiais ir musėmis bei nuo užsikrėtimo apsaugoti.
duoseptic
bausch health ireland limited - oktenidino dihidrochloridas/fenoksietanolis - odos purškalas (tirpalas) - 1 mg/20 mg/ml - octenidine, combinations
imodium
mcneil healthcare (ireland) limited - loperamido hidrochloridas - kietosios kapsulės - 2 mg - loperamide
alyr
bausch health ireland limited - cetirizino dihidrochloridas - plėvele dengtos tabletės - 10 mg - cetirizine
tegsedi
akcea therapeutics ireland limited - inotersen natrio - amiloidozė - kiti nervų sistemos vaistai - gydyti 1 ir 2 etapų polyneuropathy suaugusiųjų pacientams, sergantiems paveldima transthyretin amiloidozė (hattr).
kalydeco
vertex pharmaceuticals (ireland) limited - ivakaftoras - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
beovu
novartis europharm limited - brolucizumab - drėgnas makulos degeneravimas - oftalmologai - beovu yra nurodyta suaugusiųjų gydymas neovascular (šlapias) su amžiumi susijusios geltonosios dėmės degeneracija (amd).
avamys
glaxosmithkline (ireland) limited - flutikazono furoatas - rhinitis, allergic, seasonal; rhinitis, allergic, perennial - nosies preparatai, kortikosteroidai - suaugusiems, paaugliams (12 metų ir vyresni) ir vaikai (6-11 metų). avamys skiriamas alerginio rinito simptomų gydymui.
azarga
novartis europharm limited - brinzolamido, timololio maleatas - glaucoma, open-angle; ocular hypertension - oftalmologai - suaugusiems pacientams, kuriems yra atvirojo kampo glaukoma arba akių hipertenzija, mažėja intraokulinis slėgis (iop), kuriems monoterapija sukelia nepakankamą stemplės sumažėjimą.